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ABSTRACT  18 
The four dengue virus serotypes (DENV-1-4) cause the most prevalent mosquito-borne viral 19 
disease of humans worldwide. DENV-2 Asian 1 (A1) genotype viruses replaced the Asian-20 
American (AA) genotype in Vietnam and Cambodia, after which A1 viruses containing Q or M 21 
at envelope (E) residue 160 became more prevalent than those with 160K in both countries 22 
(2008-2011). We investigated whether these substitutions conferred a fitness advantage by 23 
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 2 
measuring neutralizing antibody titer against reporter virus particles (RVPs) representing AA, 24 
A1-160K, A1-160Q, and A1-160M using patient sera from Vietnam and a well-characterized 25 
Nicaraguan cohort. Surprisingly, we found that A1-160Q and A1-160M RVPs were better 26 
neutralized by heterologous antisera than A1-160K. Despite this, Vietnamese patients infected 27 
with A1-160Q or A1-160M viruses had higher viremia than those infected with A1-160K. We 28 
thus find that independent lineages in Vietnam and Cambodia acquired a substitution in E that 29 
significantly increased polyclonal neutralization, but nonetheless were successful in 30 
disseminating and infecting human hosts.  31 
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The four dengue virus serotypes (DENV-1-4) cause the most medically important arthropod-38 
borne viral disease of humans worldwide. Up to 96 million dengue cases occur annually, 39 
including 500,000 hospitalizations due to severe disease [1]. Within each DENV serotype, 40 
multiple genetically distinct lineages have evolved in geographically separated regions [2]. 41 
Historically in Asia and increasingly in Latin America, all four DENV serotypes and often 42 
multiple genotypes and/or clades of each serotype circulate simultaneously for extended periods 43 
of time [3]. Antigenic differences between lineages are thought to contribute to disease severity, 44 
epidemic cycling, and viral evolution [4-7].  45 
Particular DENV genotypes generally have synchronized epidemic cycles and cause the 46 
majority of disease for 3-5 years, then become scarce as prevalence of another DENV serotype 47 
increases [8]. During periods of serotype dominance, diversification is often observed for all 48 
lineages of that serotype, but as serotype incidence wanes, one lineage disappears while another 49 
persists [5-7, 9-12]. Some lineage replacements result from competing clades and genotypes that 50 
evolve in close proximity for years, while others are due to introduction of a foreign lineage [6, 51 
13].  52 
One hypothesis is that lineage replacement is stochastic, driven largely by mosquito and 53 
virus population bottlenecks, such as annual dry periods with low transmission [9, 12, 14-16]. 54 
Another hypothesis is natural selection, as lineage replacement events occur over multiple years, 55 
suggesting a gradual effect by a selective pressure [6]. Furthermore, some clade replacement 56 
events coincide with dynamic changes in the prevalence of co-circulating serotypes, suggestive 57 
of interaction/competition between antigenically distinct viruses [5]. 58 
Two general mechanisms can explain why one virus population may gain a selective 59 
advantage over another. First, the dominant clade may have an intrinsic fitness advantage, such 60 
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as greater viral replication and dissemination in mosquitoes or humans [7, 17]. Alternatively, the 61 
dominant clade may have an extrinsic fitness advantage conferred by superior transmission in the 62 
presence of host immunity [4, 18]. As for all antigenically variable pathogens, a clade that 63 
evades prior host immunity would be able to infect more hosts and replicate better than one 64 
constrained by host immunity. However, unique to DENV, a clade that takes advantage of prior 65 
host immunity via antibody-dependent enhancement of infection may also have a selective 66 
advantage in the face of population immunity [6, 19, 20].  67 
DENV is composed of 90 homo-dimers of envelope (E) glycoprotein, the main antigenic 68 
target for neutralizing antibodies. E is composed of three domains (EDI, EDII, and EDIII) [21]. 69 
EDI is the central structural domain, while EDII contains the highly conserved fusion loop that 70 
allows for virus-host membrane fusion. Finally, EDIII contains an immunoglobulin-like fold 71 
likely involved in receptor binding [22]. Strongly neutralizing human antibodies target EDIII and 72 
the hinge region between EDI and EDII [1, 23-28]. The fusion loop region is targeted by both 73 
strongly and weakly neutralizing cross-reactive antibodies [29, 30]. Substitution of just a few 74 
amino acid positions can substantially alter DENV type-specific neutralization [31], and 75 
antigenic differences between genotypes have been described using monoclonal antibodies [32], 76 
as well as antisera from experimentally inoculated animals, human vaccine recipients, and 77 
naturally infected humans [4, 7, 33, 34].  However, the specific amino acid substitutions/epitopes 78 
that determine lineage differences as recognized by polyclonal sera have not been identified.  79 
Between 2004 and 2008, the DENV-2 Asian 1 (A1) genotype began replacing the 80 
resident Asian-American DENV-2 (AA) genotype in Vietnam and Cambodia. In both countries, 81 
the genotype replacement was followed by years of DENV-1 circulation, with DENV-2 again 82 
emerging as the dominant serotype a few years later. A study found that A1-infected patients had 83 
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higher viremia than AA-infected patients, although no significant difference in replication in 84 
mosquito cells or mosquito infectivity was noted [13]. We sought to investigate the possible role 85 
of pre-existing immunity in driving the genotype replacement and subsequent evolution of the 86 
A1 lineage. 87 
Here, we describe the unusual observation of a naturally occurring substitution in the E 88 
protein of successful DENV-2 A1 lineages that appears to confer an antigenic fitness cost. 89 
During the replacement of the AA by the A1 genotype in Vietnam and Cambodia, three separate 90 
lineages arose almost simultaneously with substitutions at E position 160 (two with K160M and 91 
one with K160Q). We explored the possible role of pre-existing immunity on selection of these 92 
viruses by testing polyclonal sera against RVPs representing the previously circulating AA as 93 
well as three A1 E-160 variants. Surprisingly, A1-160Q and A1-160M RVPs were better 94 
neutralized by polyclonal sera in vitro than A1-160K and AA RVPs. Despite this apparent fitness 95 
disadvantage, we found that lineages with 160Q and 160M increased in prevalence in both 96 
countries over time and achieved higher viremia in patients than lineages with A1-160K. 97 
 98 
METHODS  99 
Cloning of RVPs structural plasmids  100 
RVPs were produced as previously reported [35]. One plasmid encodes the West Nile Virus 101 
(WNV) non-structural proteins (NS1-NS5) with a green fluorescent protein (GFP) reporter 102 
protein substituting the structural proteins (provided by T.C. Pierson, NIH), and the second 103 
plasmid encodes the DENV structural C-prM-E proteins. Structural genes of the DENV-2 104 
reference strain 16681 were first cloned into a pcDNA3.1/V5-His-TOPO vector (provided by 105 
T.C. Pierson) and served as a cloning intermediate. Substitutions were then made in the 16681 C-106 
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prM-E plasmid using the QuikChange Site-Directed Mutagenesis kit (Stratagene) to construct 107 
the AA genotype and A1 genotype variants A1-160K, A1-160Q, and A1-160M (Table 1).  108 
 109 
Generation of RVPs  110 
To produce RVPs, 4x105 cells were plated per well of a 6-well plate and incubated overnight at 111 
37°C in high-glucose DMEM medium supplemented with 10% Fetal Bovine Serum (FBS; 112 
Gibco) and penicillin/streptomycin solution (Gibco). The WNV reporter replicon (1µg), the 113 
DENV C-prM-E plasmid (3µg), and MIRUS TransIT-LT1 Transfection Reagent (12µl) were 114 
transfected into 293T cells according to the manufacturer’s protocol and incubated for 4 hours 115 
(h) at 37°C. The medium was then changed to low-glucose DMEM medium supplemented with 116 
10% FBS and penicillin/streptomycin and incubated for 20h at 37°C and 48h at 28°C. The RVP-117 
containing supernatant was harvested and frozen at -80°C.  118 
 119 
Serum samples 120 
The Nicaraguan Pediatric Dengue Cohort Study [36] was approved by the Institutional Review 121 
Boards of the University of California, Berkeley, and the Nicaraguan Ministry of Health; 18 122 
serum samples collected following primary DENV-1 infection (post-primary DENV-1 samples), 123 
10 post-primary DENV-2 samples, 40 post-secondary DENV-2 samples, and 20 post-primary 124 
DENV-3 samples were used in neutralization assays. Vietnamese plasma samples used for 125 
neutralization tests were from tetanus patients admitted to the Hospital for Tropical Diseases in 126 
1997-1998 (prior to the AA-A1 genotype replacement event; n=25) and 2006-2007 (after the 127 
replacement event; n=27). The scientific and ethics committee of the Hospital for Tropical 128 
Diseases (HTD) in Ho Chi Minh City approved the use of these anonymized, pre-collected 129 
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plasma samples for infectious disease research. De-identified plasma viremia samples analyzed 130 
were from Vietnamese patients hospitalized in the HTD with dengue in 2011 [37].    131 
 132 
RVP titration and quality control  133 
Raji-DC-SIGN cells (gift from B. Doranz, Integral Molecular), a human B cell lymphoma line 134 
with the DENV attachment factor DC-SIGN [29], were used for the RVP neutralization assay as 135 
described (Supplementary Figure 1A) [38]. For each RVP lot, the optimal working dilution 136 
was determined by titration [38]. To ensure that the antibody-RVP interaction only depended on 137 
the neutralization capacity of the antibodies in the serum and was not influenced by the amount 138 
of RVPs used, consistent with the law of mass action [39], we performed neutralization assays 139 
with a polyclonal DENV-positive control (20 pooled sera from Nicaraguan National Blood 140 
Center donors) with concentrations of RVPs above and below the optimal dilution determined 141 
from the titration of each lot. The neutralization curves, all with similar NT50 values for the three 142 
dilutions, are shown in Supplementary Figure 1B [39].  143 
 144 
Neutralization assay  145 
RVPs were diluted in RPMI complete medium (pH 8.0). RVP neutralization assays were 146 
performed as previously described using serial 3-fold dilutions of sera/plasma [38]. Infection of 147 
cells was quantified after 48h by measuring GFP-positive cells via flow cytometry and analyzed 148 
using FlowJo software. Raw data were graphed as percent infection versus the log of the 149 
reciprocal serum dilution, and a sigmoidal dose response curve with a variable slope was 150 
generated using GraphPad Prism 5.0 to determine the antibody dilution at which a 50% reduction 151 
in infection was observed compared to the no-antibody control (NT50) [38, 40]. Stringent QC 152 
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rules, including ensuring that viral particles were neutralized according to the law of mass action, 153 
the absolute sum of squares was <0.2, and the coefficient of determination (R2) of the non-linear 154 
regression was >0.9, were used to ensure reproducibility of results. Monoclonal antibodies 155 
(MAbs) were obtained as follows: E76, E87, E60, E28, and E18 (M.S Diamond, Washington 156 
University in St. Louis) [41]; 87.1 and 82.11 (Federica Sallusto and Antonio Lanzavecchia, 157 
Institute for Research in Biomedicine) [23]; 4G2 (ATCC). 158 
 159 
Phylogenetic analyses 160 
The sequence set for phylogenetic analyses consisted of all full-length DENV-2 E genes labeled 161 
as isolates from Vietnam and Cambodia that were available in GenBank as of June 2015 162 
(n=261). For the phylogenetic tree, a set that represented DENV-2 genetic diversity was also 163 
included (n=13).  Phylogenetic relationships were inferred with the maximum likelihood (ML) 164 
method (version 3.0; http://www.atgc-montpellier.fr/phyml/) using the general time reversible 165 
(GTR) nucleotide substitution model with four discrete gamma (Γ) categories of among-site rate 166 
variation, allowing for invariant sites (GTR+Γ4+I model). The ML tree topology was estimated 167 
using Nearest Neighbor Interchange (NNI) and Subtree Pruning and Regrafting (SPR) branch-168 
swapping.  Trees are unrooted but are drawn with American genotype DENV-2 as the out-group.  169 
 170 
RESULTS  171 
Greater neutralization of A1-160Q compared to AA RVPs by Vietnamese serum samples 172 
from two different periods  173 
We hypothesized that the A1 genotype may have succeeded in replacing the AA genotype by 174 
acquiring substitutions that allowed it to better escape population immunity. We first generated 175 
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RVPs representing AA and A1 to analyze their neutralization profiles with population-level 176 
patient sera collected in Vietnam before and after the AA/A1 genotype replacement. Starting 177 
with A1 DENV-2 reference strain 16681, we used site-directed mutagenesis to introduce amino 178 
acid substitutions to generate the consensus of either the A1 or AA genotype, which differ at 179 
thirteen amino acids in E (Table 1). We initially constructed an A1 RVP with Q at position 160 180 
(A1-160Q), as it was a major variant in 2006 when AA was almost fully replaced by A1 in 181 
Vietnam. We infected human Raji-DC-SIGN cells with A1-160Q and AA RVPs in the presence 182 
of two sets of Vietnamese plasma samples: 25 samples collected in 1997-98, prior to the A1/AA 183 
lineage replacement, and 27 samples collected in 2006-07, after the lineage replacement. Both 184 
sets were from tetanus patients with unknown prior DENV immune history.  185 
DENV neutralization assays can vary from laboratory to laboratory [42]; here, we used a 186 
flow cytometry-based system with human cells, implemented with stringent quality control 187 
measures to ensure reproducibility [38]. As expected, AA RVPs were better neutralized by 188 
Vietnamese sera collected after the major DENV-2 epidemic (2006-07) than before (1997-98), 189 
suggesting that years of intense AA transmission increased the magnitude of the neutralizing 190 
antibody response against the AA genotype (Figure 1A). No significant difference in NT50 titers 191 
was observed when A1-160Q RVPs were tested with 2006-07 compared with 1997-98 192 
Vietnamese patient sera (Figure 1B). However, when we compared the neutralization titers of 193 
the A1-160Q relative to the AA RVPs, we found A1-160Q RVPs were better neutralized by both 194 
the pre- (Figure 1C) and post- (Figure 1D) DENV-2 epidemic Vietnamese sera. This 195 
observation raised the unusual possibility of a virus with an apparent fitness disadvantage arising 196 
naturally in an endemic setting. 197 
 198 
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Post-primary DENV-2 AA infection sera neutralize A1-160Q and AA equally, but post-199 
secondary DENV-2 AA sera neutralize A1-160Q better than AA 200 
We further probed the difference between A1 and AA DENV-2 genotypes by titrating the RVPs 201 
against a panel of sera from the Nicaraguan Pediatric Dengue Cohort Study, which has been 202 
ongoing for 12 years and provides continuous monitoring of all DENV infections that occur in 203 
the cohort [43, 44]. This allows for identification of the infecting DENV serotype in primary as 204 
well as secondary infections [38]. Coincidentally, all DENV-2 viruses circulating in the 205 
Nicaraguan cohort were AA genotype, enabling us to test the role of primary AA and secondary 206 
AA immunity against the A1 and AA lineages. With primary DENV-2 sera, we did not observe 207 
significant differences between neutralization of genotypes A1-160Q and AA (Figure 2A). 208 
However, post-secondary DENV-2 infection sera better neutralized A1-160Q compared to AA 209 
RVPs (Figure 2B). This unexpected observation suggested that A1-160Q viruses may be better 210 
neutralized by serotype cross-reactive antibodies.  211 
 212 
Changes in prevalence of A1-160K, A1-160Q, and A1-160M following the AA/A1 genotype 213 
replacement 214 
We estimated the phylogenetic and temporal relationships among all DENV-2 E genes listed as 215 
from Vietnam and Cambodia in GenBank and identified two distinct lineages with variation at E-216 
160 that arose in Vietnam in 2006: one with A1-160Q and another with A1-160M (Figure 3). 217 
The proportion of A1 isolates with 160Q or M increased until 2008, at which point DENV-1 218 
genotype I viruses were the dominant serotype (2007-2010) and no DENV-2 was sequenced 219 
from clinical cases, although DENV-2 did circulate at low levels during this period. When 220 
DENV-2 re-emerged as the dominant serotype in 2011, the majority of A1 sequenced in Vietnam 221 
 11 
contained 160Q (65%), with a smaller number of A1-160M and K viruses still in circulation 222 
(Table 2).  223 
While the A1-160Q/M substitution arose in Vietnam, a distinct lineage of A1-160M 224 
simultaneously emerged in Cambodia. Although fewer sequences were available on GenBank 225 
from Cambodia, all isolates of A1 in Cambodia before 2005 contained 160K. However, in 2007, 226 
a lineage of A1 emerged containing 160M, and by 2008, when DENV-1 genotype I also 227 
dominated in Cambodia, A1-160M was more commonly isolated than A1-160K (Table 2). 228 
Although few isolates are available on GenBank after 2008, virological data from Cambodia 229 
indicates that A1-160M continued to be isolated in 2010 and 2011 (Philippe Buchy, personal 230 
communication). Thus, based on analyses of the available sequences in GenBank, it appears that 231 
as DENV-1 genotype I became dominant in both Vietnam and Cambodia, A1 DENV-2 viruses 232 
evolved two different amino acids substitutions at E position 160 in three independent lineages.  233 
 234 
Post-secondary DENV-2 and post-primary DENV-1 and DENV-3 sera neutralize A1-160Q 235 
and AI-160M better than A1-160K 236 
The physiochemical properties of the variants at position 160 differ; the initial lysine (K) is 237 
positively charged, while glutamine (Q) is polar uncharged and methionine (M) is hydrophobic. 238 
Position 160, located in a valley on the surface of EDI (Supplementary Figure 2A), is a contact 239 
residue of two potently neutralizing type-specific DENV-1 human antibodies, 1F4 [45] and 240 
HM14c10 [46], and is adjacent to a site shown to substantially alter DENV-1 type-specific 241 
immunity [31]. In DENV-3 viruses, position 160 is adjacent to the site of amino acid deletions 242 
(E157 and E158 in DENV-1, -2, and -4 are absent in DENV-3).   243 
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 To investigate whether the difference in serotype cross-reactive neutralization by 244 
human sera was due to amino acid variation at E-160, we generated A1-160K and A1-160M 245 
RVPs and compared their neutralization by Nicaraguan sera from post-primary DENV-1 and 246 
post-primary DENV-3 infections, as well as post-secondary DENV-2 infections. Interestingly, 247 
the high neutralization titers to A1-160Q RVPs were significantly reduced when the A1-160K 248 
RVPs were tested with Nicaraguan cohort sera from post-secondary DENV-2 infections (Figure 249 
4A, p<0.0001), post-primary DENV-1 infections (Figure 4B, p<0.0001), and post-primary 250 
DENV-3 infections (Figure 4C, p<0.0001). Like A1-160Q, A1-160M RVPs were also 251 
significantly better neutralized by post-secondary DENV-2 infection sera than A1-160K RVPs 252 
(Figure 4D, p=0.0369). Thus, A1-160Q, and to some extent A1-160M, changed the 253 
neutralization profile of polyclonal sera to A1 RVPs, making them significantly better neutralized 254 
by serotype-cross-reactive sera. 255 
 256 
Substitution at E-160 does not result in an overall change to virion structure 257 
Amino acid substitutions may affect antibody binding by directly modifying the corresponding 258 
epitope, but they can also affect distant sites by causing a global change to virion structure or 259 
affecting the number of epitopes exposed by the virion through “breathing” [47]. To test whether 260 
the 160Q and 160M substitutions modified cross-reactive antibody binding by inducing a global 261 
change to virion structure, we tested the neutralization profiles of A1-160Q and A1-160K RVPs 262 
using a panel of MAbs. We tested MAb 87.1 and E76 (which target the EDIII A strand, a cryptic 263 
viral epitope only accessible with viral breathing or global changes to virion structure), E87 264 
(which targets the EDIII C-C loop in the lateral ridge), and MAbs E60, 82.11, E28, E18, and 4G2 265 
(which target the EDII fusion loop) against A1-160Q and A1-160K RVPs, but did not find 266 
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significant differences in their NT50 titers (Supplementary Figure 2B). The target of E76 in the 267 
EDIII A strand is a temperature-dependent epitope, but we observed similar E76 neutralization 268 
profiles of A1-160Q and A1-160K at two different temperatures (4°C and 23°C) 269 
(Supplementary Figure 2C). These data provide preliminary evidence that the substitution at 270 
position 160 does not alter the overall virion structure and suggest that heterologous antibodies 271 
sensitive to the 160 substitutions may directly target an epitope that includes position 160. 272 
 273 
Individuals infected with A1-160Q have significantly higher viremia than those infected 274 
with A1-160K 275 
We hypothesized that Q and M at position 160, rather than K, must have some in vivo fitness 276 
advantage to explain their evolutionary success, despite apparently being better neutralized by 277 
polyclonal sera. We compared plasma viremia data for 70 Vietnamese adults infected with A1 278 
viruses in 2011. Of these, 70% were secondary, 11% primary, and 19% indeterminate DENV 279 
infections. Primary and secondary DENV infections were classified as previously described [37].  280 
The majority (67%) were drawn on day 3 of illness, with 24% on day 2 and 8% on day 4.  Adults 281 
infected with A1-160Q/M were statistically more likely to have secondary immune responses 282 
than those infected with A1-160K (83% versus 43%, 2-sample test for equality of proportions 283 
with continuity correction, p<0.002).  The day of viremia measurement did not differ 284 
significantly between groups (0.17 days, p=0.23, two-sided t-test). 285 
On average, individuals infected with A1-160Q/M had 4-fold higher viral titers than 286 
those infected with A1-160K (A1-160Q/M=8.05 log10(RNA copies/mL), A1-160K=7.42 287 
log10(RNA copies/mL), difference in log10(RNA copies/mL)=0.63; p=0.03, as measured by 288 
linear regression). The difference in viremia between A1-160Q/M and A1-160K remained 289 
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significant when controlling for day of illness (difference in log10(RNA copies/mL)=0.59, 290 
p<0.05) and only modestly decreased when also controlling for immune status (difference in 291 
log10(RNA copies/mL)=0.50, p=0.12).  Figure 5 shows the cumulative distributions of viremia 292 
titers for those infected with A1-160K compared with A1-160Q/M, along with the raw viremia 293 
data. Thus, although A1-160Q and A1-160M were better neutralized by serotype cross-reactive 294 
sera in vitro, viruses with these substitutions achieved higher viremia levels in vivo and were 295 
more often observed to cause secondary infections, providing a possible explanation for their 296 
increasing rate of detection in clinical cases in Vietnam and Cambodia.  297 
 298 
DISCUSSION  299 
Here we report a naturally occurring single substitution in E that significantly alters polyclonal 300 
neutralization. We observed that A1 DENV-2 lineages circulating in both Cambodia and 301 
Vietnam underwent an amino acid substitution at E position 160, making the viruses more 302 
susceptible to in vitro polyclonal antibody neutralization, yet more evolutionarily successful. 303 
Based on available DENV-2 E gene sequences, three separate lineages, two with 160M and one 304 
with 160Q, arose simultaneously in Vietnam and Cambodia in 2006-2007, and in both countries 305 
increased in relative rate of isolation over time. Further, individuals infected with A1-160M and 306 
A1-160Q viruses had significantly higher early viremia levels than those infected with A1-160K 307 
isolates and were more likely to occur in secondary infections. Our findings suggest that A1-308 
160Q and A1-160M substitutions confer a fitness advantage, which allows them to overcome the 309 
fitness cost of being better neutralized by serotype cross-reactive sera. However, the specific 310 
causal mechanisms underlying the evolutionary success of the A1-160M and A1-160Q lineages 311 
remain elusive.  312 
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One scenario is that A1-160Q, and possibly A1-160M, are more successful at replicating 313 
in the presence of poorly neutralizing heterotypic antibodies by taking advantage of antibody-314 
dependent enhancement. Globally, DENV-2 is more often isolated from secondary infections 315 
[48], and based on our findings, it is plausible that A1-160Q and A1-160M replicate better in 316 
DENV-immune individuals than A1-160K. An alternate scenario is that the substitution at 317 
position 160 results in an intrinsic fitness advantage in humans and possibly mosquitoes, 318 
improving viral replication and dissemination independent of pre-existing anti-DENV antibodies 319 
[7, 17].   320 
It is possible that another mutation in the genome explains the fitness advantage. We 321 
searched for other variants in E, but position 160 was the only highly variable position; the next 322 
most variant site, position 201, was 96% conserved. Full genomes are not available for the 70 323 
viremic adults we studied. However, for all full-length sequences of Vietnamese DENV-2 Asian 324 
1 viruses in GenBank (n=127), E position 160 was the only major variant (>20% variation) in 325 the E gene. Two positions in the NS5 gene (one in the methyltransferase and one in the 326 
polymerase) were major variants, but distinct amino acids at these positions did not directly 327 
correlate with E-160 variants.  328 
In conclusion, the successful emergence and expanded circulation for multiple years in 329 
Vietnam and Cambodia of viruses with a substitution in the E protein (K160Q, K160M) that 330 
induces increased susceptibility to cross-neutralization calls for an expanded view of the 331 
mechanism(s) of selection driving DENV evolution.  332 
 333 
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Figure Legends 379 
 380 
Figure 1. Neutralization titers to A1-160Q RVPs and AA RVPs in Vietnamese serum 381 
samples from two different periods, 1997-98 and 2006-07. RVPs were incubated with 3-fold 382 
serial dilutions of serum from Vietnamese samples. The RVP-serum mixture was then used to 383 
infect Raji-DC-SIGN cells, and after 48 hours, GFP expression was recorded by flow cytometry 384 
and used to calculate the percentage of infection. The NT50 was calculated, and the log2 of the 385 
NT50 value were plotted on the Y-axis. Prism Graphpad was used to compare the NT50 between 386 
(A) AA RVPs: Vietnamese serum samples from two different periods, 1997-98 and 2006-07; (B) 387 
A1-160Q RVPs: Vietnamese serum samples from two different periods 1997-98 and 2006-07; 388 
(C) A1-160Q RVPs and AA RVPs for Vietnamese serum samples from 1997-98; and (D) A1-389 
160Q RVPs and AA RVPs for Vietnamese serum samples from 2006-07.  390 
 391 
Figure 2. Neutralization titers to A1-160Q RVPs and AA RVPs in serum samples from the 392 
Nicaraguan Pediatric Dengue Cohort Study. Neutralization assays were performed as 393 
described in the legend for Figure 1. Neutralization titers were compared between A1-160Q 394 
RVPs and AA RVPs using (A) Nicaraguan post-primary DENV-2 infection sera; (B) Nicaraguan 395 
post-secondary DENV-2 infection sera.  396 
 397 
Figure 3. Phylogenetic tree of Vietnamese and Cambodian DENV-2 isolates. Maximum 398 
likelihood phylogenetic tree of the ancestral relationships among full-length DENV-2 E gene 399 
sequences from Vietnam and Cambodia, and 13 DENV-2 reference sequences. Strain names are 400 
 20 
colored by amino acid at position 160. The background of the tree is shaded to indicate genotype 401 
and country for relevant lineages. A time-series (right) shows the year of virus isolation.  402 
 403 
Figure 4. A1-160Q, A1-160M and A1-160K RVP variants were tested against Nicaraguan 404 
serum samples from the Pediatric Dengue Cohort Study (2004 to present). Neutralization 405 
assay were performed as described in the legend to Figure 1. Neutralization titers were compared 406 
between A1-160Q RVPs and A1-160K RVPs using (A) Nicaraguan post-secondary DENV-2 407 
infection sera; (B) Nicaraguan post-primary DENV-1 infection sera; and (C) Nicaraguan post-408 
primary DENV-3 infection sera. (D) Neutralization titers were compared between A1-160M 409 
RVPs and A1-160K RVPs using Nicaraguan post-secondary DENV-2 infection sera. 410 
 411 
Figure 5. Viremia levels of 70 Vietnamese patients infected with A1-160K, Q, and M in 412 
2011. (A) Cumulative density plot of log10(RNA copies/mL) for infected with A1-160K or M 413 
(n=23 and n=2, respectively), A1-160Q (n=45). Linear regression shows the effect of infecting 414 
virus (A1-160Q/M vs. K) on viremia levels: black line corresponds to the difference in viremia 415 
levels (a significant difference, p=0.03) and average values for those infected with A1-160Q/M 416 
and A1-160K are printed adjacent to the line. (B) Jitter plot of log10(RNA copies/mL) in 417 
individuals infected with A1-160K or A1-160Q/M.   418 
 419 420 
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 Table 1. Amino acid positions of DENV-2 E protein at which DENV-2 prototype strain (16681) and representative Vietnamese 
Asian 1 and Asian/American genotypes differ.  
 Position  
6  
83  
120  129  141  160  
164  203  226  228  308  346  461  478  484  485  491  
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Table 2. Increasing percentage of A1_160Q virus over time in Vietnam and A1-160M in 
Cambodia.*  
 
Year 1988 2001 2002 2003 2004 2005 2006 2007 2008 2011 
Vietnam           
160K 1 - - 11 3 2 44 34 1 23 
160Q 0 - - 0 0 0 12 22 5 47 
160M 0 - - 0 0 0 5 3 1 2 
% Q (Vietnam) 0 - - 0 0 0 20% 37% 71% 65% 
Cambodia           
160K - 2 5 9 3 5 0 5 6 2 
160M - 0 0 0 0 0 0 2 18 2 
% M 
(Cambodia) 
- 0 0 0 0 0 0 28% 75% 50% 
* Analysis was based on sequence analysis of E protein aa 160 using all isolate with Vietnam and 
Cambodia in name from GenBank.  
- = not available  
 
 
Supplementary Figure 1. RVP flow cytometry-based neutralization assay. (A) Experimental 547 
design for the flow cytometry-based neutralization assay. RVPs are incubated with serial 548 
dilutions of the serum/antibody mixture, and then the RVP-serum mixture is used to infect Raji-549 
DC-SIGN cells. After 48 hours, GFP expression is recorded by flow-cytometry and used to obtain 550 
the percentage of infected cells. (B) Neutralization curves of two representative preparations of 551 
Vietnamese AA (left panel) and A1-160Q (right panel) RVPs. Three concentrations of RVPs 552 
were used to infect Raji-DC-SIGN cells in the presence or absence of 3-fold serial dilutions of 553 
pooled Nicaraguan polyclonal sera (NPS). The percentage of cells expressing GFP was calculated 554 
relative to that without NPS to calculate the relative percentage of infection. 555 
 556 
Supplementary Figure 2. Substitution at E protein position 160 does not result in an overall 557 
change in virion structure. (A) PyMOL structural analysis reveals that aa160 is located in a 558 
valley on the surface of E (Domain I; EDI) based on the crystal structure of DENV-2 E protein 559 
(1OAN).  EDI is shown in red, EDII in yellow, EDIII in blue, and the second monomer in the 560 
dimer is shown in cyan. Arrows indicate the residue of interest highlighted in green.  The top 561 
panel is the cartoon representation, while the bottom panel shows the surface of the E dimer. (B) 562 
Similar neutralization profile of A1-160Q and A1-160K as tested by a panel of monoclonal 563 
antibodies, including MAbs 87.1 and E76 (which target the EDIII A strand), MAb E87 (which 564 
targets the EDIII C-C loop in the lateral ridge), and MAbs E60, 82.11, E28, E18, and 4G2 (which 565 
target the EDII fusion loop). (C) Similar neutralization profile of MAb E76, which targets the 566 
temperature-dependent A strand epitope on EDIII, against A1-160Q and A1-160K RVPs at two 567 
different temperatures (23°C and 4°C).   568 
 569 
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